190 related articles for article (PubMed ID: 31761739)
1. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy.
Gifford AH; Mayer-Hamblett N; Pearson K; Nichols DP
J Cyst Fibros; 2020 Sep; 19(5):762-767. PubMed ID: 31761739
[TBL] [Abstract][Full Text] [Related]
2. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
[TBL] [Abstract][Full Text] [Related]
3. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
Saiman L
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
[TBL] [Abstract][Full Text] [Related]
4. Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.
Goetz DM; Frederick CK; Perez G; Borowitz D
Pediatr Pulmonol; 2023 Aug; 58(8):2375-2380. PubMed ID: 37232336
[TBL] [Abstract][Full Text] [Related]
5. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
[TBL] [Abstract][Full Text] [Related]
6. Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators.
Sathe M; Moshiree B; Aliaj E; Lee M; Hudson J; Gifford A; Attel S; Gamel B; Freedman SD; Schwarzenberg SJ; Freeman AJ
Pediatr Pulmonol; 2023 Mar; 58(3):811-818. PubMed ID: 36448312
[TBL] [Abstract][Full Text] [Related]
7. Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators.
Wajda KE; Roesch EA; Gifford AH
Curr Opin Pulm Med; 2023 Nov; 29(6):580-586. PubMed ID: 37611027
[TBL] [Abstract][Full Text] [Related]
8. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis.
Talwalkar JS; Koff JL; Lee HB; Britto CJ; Mulenos AM; Georgiopoulos AM
Psychosomatics; 2017; 58(4):343-354. PubMed ID: 28576305
[TBL] [Abstract][Full Text] [Related]
9. Fertility and Pregnancy in Cystic Fibrosis.
Shteinberg M; Taylor-Cousar JL; Durieu I; Cohen-Cymberknoh M
Chest; 2021 Dec; 160(6):2051-2060. PubMed ID: 34284004
[TBL] [Abstract][Full Text] [Related]
10. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
Albright JC; Houck AP; Pettit RS
Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
13. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Bessonova L; Volkova N; Higgins M; Bengtsson L; Tian S; Simard C; Konstan MW; Sawicki GS; Sewall A; Nyangoma S; Elbert A; Marshall BC; Bilton D
Thorax; 2018 Aug; 73(8):731-740. PubMed ID: 29748252
[TBL] [Abstract][Full Text] [Related]
14. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
15. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
16. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
[TBL] [Abstract][Full Text] [Related]
17. New treatments targeting the basic defects in cystic fibrosis.
Fajac I; Wainwright CE
Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
[TBL] [Abstract][Full Text] [Related]
18. Entering the era of highly effective modulator therapies.
Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
[TBL] [Abstract][Full Text] [Related]
19. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
20. POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes.
Downey DG
Chest; 2022 Jan; 161(1):18-20. PubMed ID: 35000701
[No Abstract] [Full Text] [Related]
[Next] [New Search]
